CN103370414A - 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法 - Google Patents

降低恶性神经胶质瘤中下调肾细胞癌的表达的方法 Download PDF

Info

Publication number
CN103370414A
CN103370414A CN201180035434XA CN201180035434A CN103370414A CN 103370414 A CN103370414 A CN 103370414A CN 201180035434X A CN201180035434X A CN 201180035434XA CN 201180035434 A CN201180035434 A CN 201180035434A CN 103370414 A CN103370414 A CN 103370414A
Authority
CN
China
Prior art keywords
drr
cells
expression
antisense oligonucleotide
invasion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180035434XA
Other languages
English (en)
Chinese (zh)
Inventor
凯文·彼得雷卡
马萨德·达姆哈
格伦·德莱维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Institution for the Advancement of Learning
Original Assignee
Royal Institution for the Advancement of Learning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Institution for the Advancement of Learning filed Critical Royal Institution for the Advancement of Learning
Publication of CN103370414A publication Critical patent/CN103370414A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180035434XA 2010-05-18 2011-05-18 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法 Pending CN103370414A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34575110P 2010-05-18 2010-05-18
US61/345,751 2010-05-18
PCT/CA2011/000591 WO2011143762A1 (en) 2010-05-18 2011-05-18 Method for reducing expression of downregulated iν renal cell carcinoma iν malignant gliomas

Publications (1)

Publication Number Publication Date
CN103370414A true CN103370414A (zh) 2013-10-23

Family

ID=44991131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180035434XA Pending CN103370414A (zh) 2010-05-18 2011-05-18 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法

Country Status (7)

Country Link
US (2) US8765708B2 (https=)
EP (1) EP2571989A4 (https=)
JP (1) JP2013534410A (https=)
CN (1) CN103370414A (https=)
AU (1) AU2011256098A1 (https=)
CA (1) CA2836315A1 (https=)
WO (1) WO2011143762A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
RU2747822C2 (ru) * 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
WO2019154884A1 (en) * 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
US12104152B2 (en) 2018-03-19 2024-10-01 The Trustees Of The University Of Pennsylvania 2′F-ANA-LET7 mediated utrophin upregulation for DMD therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284966A (zh) * 1997-12-22 2001-02-21 阿斯特拉制药公司 新型g蛋白偶联受体
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20060134663A1 (en) * 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048738A1 (en) * 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
EP1737957A1 (en) * 2004-04-22 2007-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
CN101474413A (zh) * 2009-02-10 2009-07-08 四川大学 Drr1基因在制备抗肿瘤药物中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284966A (zh) * 1997-12-22 2001-02-21 阿斯特拉制药公司 新型g蛋白偶联受体
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
US20060134663A1 (en) * 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JORG VAN DEN BOOM ET AL.: "Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction", 《INT. J. CANCER》, vol. 119, no. 10, 24 July 2006 (2006-07-24), pages 2330 - 2338, XP055095210, DOI: doi:10.1002/ijc.22108 *
LIANG WANG ET AL.: "Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma", 《GENES, CHROMOSOMES & CANCER》, vol. 27, no. 1, 31 January 2000 (2000-01-31), pages 1 - 10, XP055069625, DOI: doi:10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6 *
PU LE ET AL.: "DRR drives brain cancer invasion by regulating cytoskeletal-focal adhesion dynamics", 《ONCOGENE》, vol. 29, no. 33, 14 June 2010 (2010-06-14), pages 4636 - 4647, XP055069624, DOI: doi:10.1038/onc.2010.216 *
赵新宇: "DRR1基因的表达与功能初探以及靶向PLK1基因RNAi的抗肿瘤作用", 《中国博士学位论文全文数据库（电子期刊）基础科学辑》, 15 May 2008 (2008-05-15), pages 006 - 4 *

Also Published As

Publication number Publication date
US9493772B2 (en) 2016-11-15
CA2836315A1 (en) 2011-11-24
JP2013534410A (ja) 2013-09-05
US20130197057A1 (en) 2013-08-01
EP2571989A1 (en) 2013-03-27
WO2011143762A1 (en) 2011-11-24
US20140343124A1 (en) 2014-11-20
EP2571989A4 (en) 2014-08-13
AU2011256098A1 (en) 2013-01-10
US8765708B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
EP2751128B1 (en) Cell-penetrating peptides having a central hydrophobic domain
NZ573425A (en) Fkbp-l and uses thereof
KR20120048613A (ko) Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
JP2024524291A (ja) Ｃｕｇリピートを標的とするためのアンチセンス化合物及び方法
CN116113697A (zh) 用于治疗癫痫的方法和组合物
US9493772B2 (en) Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
JP2013534410A6 (ja) 悪性神経膠腫においてｄｏｗｎ ｒｅｇｕｌａｔｅｄ ｉｎ ｒｅｎａｌ ｃｅｌｌ ｃａｒｃｉｎｏｍａの発現を減少させる方法
EP3259346A1 (en) P63 inactivation for the treatment of heart failure
US20140128450A1 (en) Cancer Therapy
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
US11566247B2 (en) Modulation of alternative MDM2 splicing
US20230151369A1 (en) Compositions and methods for inhibiting tdp-43 and fus aggregation
WO2013075233A1 (en) Method for treating brain cancer
CN112662671B (zh) 靶向SMN2启动子区甲基化位点nt-290所在区域的反义寡核苷酸
US20250127812A1 (en) Compositions and methods for engineering stable tregs
KR20230068278A (ko) Upf1 단백질 또는 upf1 단백질 유래 폴리펩티드의 암의 예방 또는 치료 용도
WO2024048528A1 (ja) 心疾患及びラミノパチーの予防及び／又は治療剤
KR20210121767A (ko) 스플라이스좀 관련 단백질인 ik의 용도
CA2707107A1 (en) Therapeutic targets and medicaments involving p230/golgin-245
JP2021153542A (ja) Ｃｂｆ１結合核酸分子およびその用途
JP2018172285A (ja) 細胞内の異常物質蓄積を伴う疾患の治療薬、バイオマーカー、診断薬、並びに、スクリーニング方法
HK1194389B (en) Cell-penetrating peptides having a central hydrophobic domain
HK1194389A (en) Cell-penetrating peptides having a central hydrophobic domain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131023